<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940202-2-00123</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> a. Collect environmental samples from potential sources of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=3 --> Aspergillus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 -->  spp., especially those sources implicated in the epidemiologic investigation, by using appropriate methods,424,427,428,472,484,488,666 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  e.g., use of a high-volume air sampler rather than settle plates. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 424  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> b. Perform molecular subtyping of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Aspergillus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp. obtained from patients and the environment to establish strain identity. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 476,477  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> c. If air-handling systems supplying high-risk patient-care areas are not optimal, consider temporary deployment of portable HEPA filters until rooms with optimal air-handling systems are available for all patients at high risk of invasive aspergillosis.469  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> CATEGORY II  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> d. If an environmental source is identified, perform corrective measures as needed to eliminate the source from the high-risk patients' environment.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> e. If an environmental source is not identified, review existing infection-control measures, including engineering aspects, to identify potential areas that can be corrected or improved.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> III. Modifying Host Risk for Infection  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A. Administer cytokines, including granulocyte colony-stimulating factor and granulocyte-macrophage stimulating factor, to increase host resistance to aspergillosis by decreasing the duration and severity of chemotherapy-induced granulocytopenia. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 464,465  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY II  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> B. NO RECOMMENDATION for administration of intranasal amphotericin B or oral antifungal agents (including amphotericin B and triazole compounds) in high-risk patients for prophylaxis against aspergillosis.466,467,667  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> UNRESOLVED ISSUE  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=5 f=1 --> Prevention and Control of Respiratory Syncytial Virus Infection <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> (The principles and recommendations below are applicable for prevention and control of nosocomial  <!-- PJG 0012 frnewline --> lower respiratory tract infections due to adenovirus, parainfluenza virus and rhinovirus.)  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=5 f=1 --> I. Staff Education and Infection Surveillance <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=5 f=1 --> A. Staff Education  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> Educate personnel about the epidemiology, modes of transmission and means of preventing spread of respiratory syncytial virus (RSV).215,611&hyph;613  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IA  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=5 f=1 --> B. Surveillance  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 1. Establish mechanism(s) by which the appropriate hospital personnel are promptly alerted to any increase in RSV activity in the local community.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 2. During periods of increased prevalence of RSV in the community (and during December&hyph;March), attempt prompt diagnosis of RSV infection by using rapid diagnostic techniques as clinically indicated in pediatric patients, especially infants, and in immunocompromised adults admitted to the hospital with respiratory illness.545,549  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=5 f=1 --> II. Interruption of Transmission of RSV <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=5 f=1 --> A. Prevention of Person-to-Person Transmission <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> 1. Primary Measures for Contact Isolation  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> a.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=3 --> Handwashing. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 -->  Wash hands after contact with a patient, or after touching respiratory secretions or fomites potentially contaminated with respiratory secretions, whether or not gloves are worn.207,503,524&hyph;526,547  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IA  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> b.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=3 --> Gloving. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 -->  (1) Wear gloves for handling patients or respiratory secretions of patients with proven or suspected RSV infection, or fomites potentially contaminated with patient secretions.215,503,524,525,543,549  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IA  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> (2) Change gloves between patients, or after handling respiratory secretions or fomites contaminated with secretions from one patient before contact with another patient.215,217 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Wash hands after removing gloves. (See II&hyph;A&hyph;1&hyph;a, above.)  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> CATEGORY IA  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> c.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Gowning. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Wear a gown when soiling with respiratory secretions from a patient is anticipated, e.g., when handling infants with RSV infection or other viral respiratory illness, and change the gown after such contact and before caring for another patient. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 215,542,544,549  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> d.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=3 --> Staffing.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> Restrict healthcare workers in the acute stages of an upper respiratory illness, i.e., those who are sneezing and/or coughing, from taking care of RSV-uninfected infants and other patients at high risk for complications from RSV infection, e.g., children with severe underlying cardio-pulmonary conditions, children receiving chemotherapy for malignancy, and patients who are otherwise immunocompromised.547,549  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> CATEGORY IB  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> e.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=3 --> Limiting Visitors.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> Do not allow persons with symptoms of respiratory infection to visit uninfected pediatric, immunosuppressed, and cardiac patients.543  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> CATEGORY II  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            